Fasted-state simulated intestinal fluid "FaSSIF-C", a cholesterol containing intestinal model medium for in vitro drug delivery development.
Pooneh Khoshakhlagh, Raphael Johnson, Peter Langguth, Thomas Nawroth, Lars Schmueser, Nadja Hellmann, Heinz Decker, Noemi Kinga Szekely
Index: J. Pharm. Sci. 104 , 2213-24, (2015)
Full Text: HTML
Abstract
A set of biorelevant media "fasted-state simulated intestinal fluid with cholesterol (FaSSIF-C)" for the in vitro study of intestinal drug dissolution in the duodenum was developed. These contain cholesterol at the same levels as in human bile: the cholesterol content of FaSSIF-7C is equivalent to healthy female, FaSSIF-10C to healthy male persons, and FaSSIF-13C to several disease cases that lead to gallstones. The fluids were studied in three aspects: biocompatibility, intestinal nanostructure, and solubilizing power of hydrophobic drugs of the BCS class II. The biocompatibility study showed no toxic effects in a Caco-2 cell system. The drug-solubilizing capacity toward Fenofibrate, Danazol, Griseofulvin, and Carbamazepine was assessed as example. It varied with the cholesterol content widely from a fourfold improvement to a twofold reduction. The nanostructure study by dynamic light scattering and small-angle neutron scattering indicated vesicles as the main component of FaSSIF-C in equilibrium (>1 h), but at high cholesterol content, larger particles were observed as a minor contribution. The neutron experiments indicated the presence of complex micelle-vesicle mixtures, even after 1 h development of fed-state bile model to FaSSIF. The results indicate that cholesterol affects some drugs in solubilization and particle size in intestinal model fluids.© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.
Related Compounds
Related Articles:
2015-05-01
[J. Virol. 89(9) , 4918-31, (2015)]
2015-01-01
[Eur. J. Pharm. Biopharm. 89 , 30-9, (2015)]
2015-01-01
[Nucleic Acids Res. 42(18) , 11433-46, (2014)]
The dynamics of giant unilamellar vesicle oxidation probed by morphological transitions.
2014-10-01
[Biochim. Biophys. Acta 1838(10) , 2615-24, (2014)]
2014-09-01
[Pharmacol. Biochem. Behav. 124 , 153-9, (2014)]